IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Severine Vermeire  1     Bruce E. Sands  2     Laurent Peyrin-Biroulet  3, 4     Geert R. D'Haens  5     Julian Panés  6     Andres Yarur  7     Doug Wolf  8     Timothy Ritter  9     Stefan Schreiber  10     Kevin Shan  11     Chris Rabbat  12     Michael Chiorean  13     Filip Baert  14     Marla C. Dubinsky  2     Martina Goetsch  15     Silvio Danese  16     Brian G. Feagan  17, 18    
1 University Hospital Leuven, Leuven, Belgium
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 University of Lorraine, CHRU-Nancy, Nancy, France
4 University of Lorraine, Inserm, NGERE, Nancy, France
5 Amsterdam University Medical Centers, Amsterdam, Netherlands
6 Formerly of Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
7 Cedars-Sinai Medical Center, Los Angeles, United States
8 Atlanta Gastroenterology Associates, Atlanta, United States
9 GI Alliance, Southlake, United States
10 University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
11 Pfizer Inc, San Diego, United States
12 Pfizer Inc, New York, United States
13 Swedish Medical Center, Seattle, United States
14 AZ Delta Deltalaan 2, Roeselare, Belgium
15 Pfizer AG, Zürich, Switzerland
16 IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
17 Western University, London, Canada
18 Alimentiv Inc, London, Canada

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing